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This is the 12th in a series of
reviews written by committees of
experts of the Nomenclature
Committee of the International
Union of Basic and Clinical
Pharmacology (NC-IUPHAR). A
listing of all articles in the series
and the Nomenclature Reports
from IUPHAR published in
Pharmacological Reviews can be
found at http://www
.GuideToPharmacology.org. This
website, created in a
collaboration between the British
Pharmacological Society (BPS)
and the International Union of
Basic and Clinical Pharmacology
(IUPHAR), is intended to become
a ‘one-stop shop’ source of
quantitative information on drug
targets and the prescription
medicines and experimental
drugs that act on them. We
hope that the Guide to
Pharmacology will be useful for
researchers and students in
pharmacology and drug
discovery and provide the
general public with accurate
information on the basic science
underlying drug action.
Since the discovery of endothelin (ET)-1 in 1988, the main components of the
signalling pathway have become established, comprising three structurally similar
endogenous 21-amino acid peptides, ET-1, ET-2 and ET-3, that activate two GPCRs,
ETA and ETB. Our aim in this review is to highlight the recent progress in ET
research. The ET-like domain peptide, corresponding to prepro-ET-193–166, has been
proposed to be co-synthesized and released with ET-1, to modulate the actions of
the peptide. ET-1 remains the most potent vasoconstrictor in the human
cardiovascular system with a particularly long-lasting action. To date, the major
therapeutic strategy to block the unwanted actions of ET in disease, principally in
pulmonary arterial hypertension, has been to use antagonists that are selective for
the ETA receptor (ambrisentan) or that block both receptor subtypes (bosentan).
Macitentan represents the next generation of antagonists, being more potent than
bosentan, with longer receptor occupancy and it is converted to an active
metabolite; properties contributing to greater pharmacodynamic and
pharmacokinetic efficacy. A second strategy is now being more widely tested in
clinical trials and uses combined inhibitors of ET-converting enzyme and neutral
endopeptidase such as SLV306 (daglutril). A third strategy based on activating the
ETB receptor, has led to the renaissance of the modified peptide agonist IRL1620 as
a clinical candidate in delivering anti-tumour drugs and as a pharmacological tool
to investigate experimental pathophysiological conditions. Finally, we discuss biased
signalling, epigenetic regulation and targeting with monoclonal antibodies as
prospective new areas for ET research.
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Abbreviations
ECE-1, endothelin-converting enzyme-1; ECE-2, endothelin-converting enzyme-2; ELDP, endothelin-like domain
peptide; ET, endothelin; HIF-1α, hypoxia inducible factor-1α; NEP, neutral endopeptidase; PAH, pulmonary arterial
hypertension
This article, written by members of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and
Drug Classification (NC-IUPHAR) subcommittee for the endothelin receptors, confirms the existing nomenclature for these receptors and
reviews our current understanding of their structure, pharmacology and functions, and their likely physiological roles in health and disease.
More information on these receptor families can be found in the Concise Guide to PHARMACOLOGY (http://onlinelibrary.wiley.com/doi/
10.1111/bph.12445/abstract) and for each member of the family in the corresponding database http://www.guidetopharmacology.org/
GRAC/FamilyDisplayForward?familyId=21&familyType=GPCR.
Introduction
Since the discovery of endothelin (ET)-1 in 1988 (Yanagisawa
et al., 1988; Inoue et al., 1989) the components of the ET
signalling pathway have become established, comprising
three structurally similar endogenous 21-amino acid pep-
tides, ET-1, ET-2 and ET-3, that activate two GPCRs, ETA (Arai
et al., 1990) and ETB (Sakurai et al., 1990). In humans, ET-2
differs from ET-1 by only two amino acids, whereas ET-3
differs by six amino acids representing more substantial
changes. ET-3 is the only isoform that can distinguish
between the two receptor subtypes, having a similar potency
at the ETA receptor as ET-1 and ET-2, but much lower affinity
than these isoforms for the ETB receptor (Figure 1). Structur-
ally, ETs are unusual among the mammalian peptides in pos-
sessing two disulphide bridges. This feature is shared by the
sarafotoxins, a family of peptides that were isolated from
snake venom in the same year as the discovery of ET-1 (Taka-
saki et al., 1988), and that provided the first selective agonist
at the ETB receptor, sarafotoxin S6C (William et al., 1991).
A number of features of the ET signalling pathway are
unusual compared with other peptidergic systems and these
continue to intrigue investigators, with over a thousand
ET-related papers still published each year. ET-1 is the most
abundant isoform in the human cardiovascular system, pre-
dominantly released from endothelial cells to cause potent
and unusually long-lasting vasoconstriction that may persist
for many hours. ET-1 is a key mediator in regulating vascular
Tables of Links
TARGETS
GPCRsa
AT1 receptors
ETA receptors
ETB receptors
GPR37
GPR37L
Hydroxycarboxylic acid receptors
μ opioid receptors
Parathyroid hormone receptors
Enzymesb
Cathepsin A
Chymase
CYP3A4
CYP2C19
Endothelin-converting enzyme 1
Endothelin-converting enzyme 2
Neutral endopeptidase
LIGANDS
5-Fluorouracil Endothelin-3
Ambrisentan IRL1620
Amyloid β-peptide KC-12615
Atrial natriuretic peptide (ANP) Losartan
β-Catenin Macitentan
Bosentan NO
BQ123 Prosaptide
BQ788 PGI2
BQ3020 Sarafotoxin S6b
Captopril Sarafotoxin S6c
Daglutril Sitaxentan
Docetaxel TGFβ1
Doxorubicin
Endothelin-1
Endothelin-2
These Tables list protein targets and ligands that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and the Concise Guide to PHARMACOLOGY
2013/14 (a,bAlexander et al., 2013a,b).
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function in the majority of organs systems balanced by
opposing vasodilators, particularly NO, prostacyclin and
endothelium-derived hyperpolarizing factor. Endothelial cell
dysfunction occurs in pathophysiological conditions such as
pulmonary arterial hypertension (PAH) and is associated with
loss of these dilators and increased synthesis of ET. The con-
sequence of this is vasoconstriction, proliferation of many
different cell types particularly vascular smooth muscle, fibro-
sis and inflammation; processes associated with vascular
remodelling. In disease, the deleterious actions of ET in the
vasculature are mainly mediated by the ETA receptor, whereas
activation of ETB receptors results in many of the beneficial
effects of the peptide that frequently act as a regulatory coun-
terbalance (Davenport and Maguire, 2006). The formation
of the disulphide bridge in the ET peptides blocks the
N-terminal amino acid conferring resistance to enzymic deg-
radation in plasma. Internalization by ETB scavenging recep-
tors is therefore particularly important for termination of the
ET signal in health and disease.
The major therapeutic strategy (Figure 1) to block the
unwanted actions of ET in disease has been to use antagonists
of ETA receptors or both receptor subtypes (Palmer, 2009)
with the first clinical application being bosentan in PAH
(Rubin et al., 2002). More recently, a second strategy has
started to be more widely tested in clinical trials using inhibi-
tors of ET-converting enzymes 1 (ECE-1; Xu et al., 1994) and
2 (ECE-2; Emoto and Yanagisawa, 1995), the major biosyn-
thetic pathway of ET (Figure 1) at least in the human vascu-
lature (Russell and Davenport, 1999a,b). A third emerging
strategy based on biosimilar agonists at the ETB receptor (mol-
ecules similar, but not identical to the endogenous ligand)
has led to the renaissance of IRL1620 as a clinical candidate in
delivering anti-tumour drugs and in other pathophysiologi-
cal conditions such as cerebral ischaemia.
The aim of this focused IUPHAR review is to highlight
recent progress and some surprising new discoveries in the
pharmacology of the ET system. The following references are
recommended for more detailed information on specific ET
research areas including the heart (Kelland and Webb, 2006;
Kirkby et al., 2008; Kohan et al., 2012; Ohkita et al., 2012;
Vignon-Zellweger et al., 2012; Drawnel et al., 2013), renal
(Dhaun et al., 2011; 2012; Kohan et al., 2011a,b; Hyndman
and Pollock, 2013), hypertension (Rautureau and Schiffrin,
2012; Speed and Pollock, 2013), PAH (Pernow et al., 2012;
Rubin, 2012; Liu et al., 2013), cancer (Bagnato et al., 2011;
Said and Theodorescu, 2012; Rosanò et al., 2013b), athero-
sclerosis and diabetes (Pernow et al., 2012).
ET peptides
Evidence for a new ET peptide: the ET-like
domain peptide (ELDP)
The ELDP has been recently identified as a peptide corre-
sponding to prepro-ET-193–166 (Yuzgulen et al., 2013) immedi-
ately adjacent to the gene sequence encoding big ET-1. The
74-amino acid peptide has been detected by HPLC and spe-
cific double recognition site immunoassays in conditioned
media from two cell lines, endothelial (EA.hy 926) and epi-
thelial (A549), as well as from primary cell cultures of human
aortic endothelial cells that are known to secrete ET-1. In the
aortic endothelial cells, the peptide was co-synthesized and
co-released with ET-1. Plasma levels in untreated patients
were 6.5 pmol·L−1, which compares with typical basal levels
of immunoreactive ET-1 of 5 pmol·L−1 (Davenport et al.,
1990). Levels of ELDP were significantly elevated in patients
with heart failure suggesting a potential use as a bio-marker.
While no effect was observed on BP in the anaesthetized rat,
intriguingly ELDP significantly increased the duration of the
pressor response of ET-1 (0.3 nmol·kg−1, likely to be a sub-
maximal dose). Pretreatment of rat mesenteric arteries with
10 nM ELDP also potentiated a submaximal response of ET-1
by fivefold (Yuzgulen et al., 2013). It is not unexpected that a
Figure 1
Scheme of the biosynthesis of ET peptides and their interaction with receptors. Based on information from the literature including Barton and
Yanagisawa (2008), Turner and Tanzawa (1997) and Lee et al. (1999).
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second peptide sharing a cleavage site with ET-1 would also
be co-released, but it is intriguing that the peptide was able to
potentiate ET-1 responses in vitro and in vivo. It is not yet
reported, using saturation or competition-binding experi-
ments, whether ELDP binds directly to ET receptors, binds to
an allosteric site or whether the peptide modulates ET
responses by other mechanisms. Intriguingly, ELDP encom-
passes the sequence of the putative ‘endothelin-like peptide’
corresponding to prepro-ET-1109–123 proposed in the original
Nature paper by Yanagisawa et al. (1988). Eight out of 15
residues in the corresponding sequence in ET-1 are identical
and the four Cys residues are perfectly conserved and flanked
by dibasic pairs that are recognized by endopeptidase process-
ing enzymes, to yield a cleaved peptide. However, a synthetic
peptide corresponding to this sequence was devoid of agonist
or antagonist activity against ET-1, in vascular preparations
(Cade et al., 1990).
Global knockout of ET-2 gene reveals distinct
phenotype compared with ET-1/ETA and
ET-3/ETB gene deletions
ET–1-deficient homozygous mice die at birth of respiratory
failure, which is secondary to severe craniofacial and cardio-
vascular abnormalities. ETA receptor and ECE-1 knockout
mice have similar morphological abnormalities (Kurihara
et al., 1994; Clouthier et al., 1998; Yanagisawa et al., 1998).
The phenotype is similar to a spectrum of human conditions,
CATCH 22 (cardiac anomaly, abnormal face, thymic hypo-
plasia, cleft palate, hypocalcaemia, chromosome 22 dele-
tions) and established the importance of the ETA/ET-1
signalling system for cardiovascular and craniofacial develop-
ment. Gene deletions for ET-3 and ETB receptors exhibit a
different and non-overlapping phenotype to ET-1/ETA-
deficient animals. They are viable at birth and survive for up
to 8 weeks, but display aganglionic megacolon, as a result of
absence of ganglion neurones, together with a disorder of the
pigment in their coats (Baynash et al., 1994; Hosoda et al.,
1994). In these mice, enteric nervous system precursors and
neural crest-derived epidermal melanoblasts fail to colonize
the intestine and skin. This phenotype resembles Hirschs-
prung’s disease in man.
Deleting genes encoding all the key molecules, ET-1, ET-3,
ETA, ETB, ECE-1 and ECE-2 has been accomplished in mice
generating important information about their effect on phe-
notype. The deletion of the gene for ET-2 has now been
reported. The physiological role of ET-2 has been puzzling. It
had been assumed that the actions of ET-2 would be similar,
if released, to the more widely distributed and abundant ET-1.
Current antagonists block both ET-2 and ET-1 with the same
potency and are not yet able to distinguish the actions of
these peptides.
A key advance in the field was the generation by Chang
et al. (2013) of a global ET-2 gene knockout mouse, which
surprisingly exhibited a distinct phenotype to global ET-1 or
ET-3 gene deletions. These mice showed severe growth retar-
dation, internal starvation characterized by hypoglycaemia,
ketonaemia and increased levels of starvation-induced genes.
Mice were profoundly hypothermic and the median lifespan
could be significantly extended by housing in a warm envi-
ronment. The intestine was morphologically and function-
ally normal, which was unexpected as murine ET-2 (see Ling
et al., 2013), also known as vasoactive intestinal contractor, is
present throughout the gastrointestinal tract suggesting, in
this tissue at least, in the absence of ET-2, ET-1 continues to
mediate signalling. In agreement, intestinal epithelium-
specific ET-2 knockout mice showed no abnormalities in
growth and survival. In marked contrast, dramatic changes
were observed in lung morphology and function. Mice had
breathing difficulties after the first week exhibiting enlarged
air spaces with substantial simplification of lung alveolar
structure, larger lung capacities leading to abnormally
elevated carbon dioxide (hypercapnia) and deficiency of
oxygen (hypoxaemia) in the blood. Hypothermia and lung
dysfunction might not be specific, but may be due to a sec-
ondary effect of internal starvation because of ET-2 defi-
ciency. However, it is possible that these studies identify an
important function for ET-2 in the pulmonary system. The
authors showed that mRNA encoding ET-2 was only present
in epithelial cells whereas receptor mRNA was mainly present
in mesenchyme, consistent with a paracrine function for ET-2
in the lung.
Pharmacological significance: is ET-2 the
inducible isoform?
The dramatic effects on the lung suggest a crucial role for ET-2
at birth, at least in mice. The lungs, and potentially the heart,
remain major therapeutic targets for ET antagonists in
humans in the treatment of PAH. In rodents, ET-2 was less
widely distributed than ET-1, mainly found in heart, lung,
ovary, stomach and all regions of the intestine (de la Monte
et al., 1995; Takizawa et al., 2005). ET-2 expression in human
tissue was similar, being present in the human heart
(Plumpton et al., 1996b), lung (Marciniak et al., 1992), kidney
(Karet and Davenport, 1996), vasculature, (Howard et al.,
1992) intestine and ovaries (Palanisamy et al., 2006), but has
not been investigated in pathophysiological tissue. In
humans, alternatively spliced mRNA variants encoding ET-2
have been detected with a specific pattern of distribution in
various tissues. Some of these variants contain sites for the
post-transcriptional processing of preproET-2 into mature
ET-2, which may be altered in a tissue-specific manner
(O’Reilly et al., 1993). The best established model of spatial
and temporal ET-2 signalling is in the ovary, a highly vascular
tissue, which undergoes cyclic changes as follicles grow,
rupture and transform into corpora lutea and eggs are peri-
odically released (Ko et al., 2012). In rats, low levels of ET-1
are constitutively expressed throughout the ovulatory cycle,
whereas ET-2 is induced transiently at much higher concen-
trations during the period of ovulation to luteal phases (Ko
et al., 2006). ET-2 is expressed in the granulosa cells of perio-
vulatory follicles, but not during other stages of follicular
development. In mice, induced superovulation results in a
dramatic increase in ET-2 mRNA expression (Palanisamy
et al., 2006). ET-2 expression surged in response to gonado-
tropin and quickly declined by 13 h, which coincided with
the time of follicular rupture. Crucially, both ET receptor
subtypes are present and their ratio does not seem to change.
Thus, the ET-2 gene appears to be switched on only when
increased levels of ET are required, with ET–2-mediated con-
traction being the final signal facilitating ovulation (Ling
et al., 2013).
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ET-1 signalling is well established in neural crest migra-
tion. In the developing mouse retina, constitutive over-
expression of ET-2 affects vascular development by inhibiting
endothelial cell migration across the retinal surface and sub-
sequent endothelial cell invasion into the retina, an action
mediated by ETA receptors. Interestingly, over-expression is
spatially localized as it has no obvious action on vascular
structures in brain or skin (Rattner et al., 2013). Constitutive
over-expression of ET-2 signalling also protected photorecep-
tors from light damage (Braunger et al., 2013). Similarly,
Bramall et al. (2013) found expression of ET-2 mRNA was
greatly increased in the photoreceptors of mouse models of
inherited photoreceptor degeneration and, using the global
ET-2 knockout mice, showed increased ET-2 expression was
protective of the mutant photoreceptors.
Case for re-evaluating the role of ET-2
Targeting the ET-2 gene in mice provides compelling evidence
that, while both ET-1 and ET-2 can coexist in the same tissue
compartments, there is a critical, but distinct ET-2 pathway. A
key role has now been established for ET-2 in ovarian physi-
ology. This may be accomplished at the level of gene expres-
sion, but differences may also exist in peptide synthesis by
ECEs and chymase, which may allow the two ET peptide
pathways to be distinguished pharmacologically and become
separate drug targets. Additionally, pharmacological differ-
ences have been identified, for example ET-2 dissociates from
receptors much more rapidly than ET-1 and higher affinity
has been reported, for example in the brain (Ling et al., 2013).
Detailed studies comparing rat mesenteric resistance and
basilar arteries demonstrated that ET-1 and ET-2 initiate and
maintain vasoconstriction by different downstream mecha-
nisms raising the prospect of ‘biased signalling’ mediated by
two structurally different agonists activating the same recep-
tor (Compeer et al., 2013).
Potential new therapeutic strategies
exploiting ETB receptor agonists
The pharmacological rationale for this strategy is that ET-1,
tonically released from endothelial cells, also interacts with
endothelial cell ETB receptors. The importance of this
counter-regulatory pathway has been underestimated to date.
Endothelial cells line the vasculature of every organ and
tissue in the body that receives blood supply. Although the
cells represent ∼1% of the weight of the vessel wall, they have
a combined mass comparable with some endocrine glands.
Crucially, ET-1 feeding back onto endothelial receptors to
release NO not only limits ETA-mediated vasoconstriction by
stimulation of vascular cGMP, but also limits further ET-1
release. Thus in the vasculature, NO and other dilators are
crucial in balancing the ET system, but these may be reduced
or absent in pathophysiological conditions.
ET-1+/− heterozygous mice developed elevated BP and mild
hypertension, rather than the fall in BP that might have been
expected. Partial deletion of the gene allows survival and
produced lower levels of ET-1 in plasma and lung tissue than
wild type (Kurihara et al., 1994). These results suggest that
ET-1 has an essential physiological role in cardiovascular
homeostasis. Low levels promote vasodilatation whereas
higher and pathophysiological concentrations of ET-1
increase BP and total peripheral vascular resistance. While
ETA receptor selective antagonists such as BQ123 (Ihara et al.,
1992) cause the expected vasodilatation in humans (Haynes
and Webb, 1994), the ETB receptor selective antagonist BQ788
(Ishikawa et al., 1994) caused systemic vasoconstriction in
healthy volunteers, showing that the main consequence of
activation of endothelial ETB receptors by tonically secreted
ET-1 was the physiological basal release of NO (Love et al.,
2000). In agreement, initial vasodilatation can be detected in
the human forearm vascular bed following infusion of low
concentrations of ET-1 whereas higher doses caused sustained
vasoconstriction (Kiowski et al., 1991). A contribution to
vasoconstriction may also be the result of occupancy by
ET-1 of the clearance ETB receptors causing an ETA-mediated
vasoconstriction.
ETB agonists in chemotherapy: IRL1620
ET-1 acting on ETA receptors has been proposed to stimulate
cell proliferation, migration, invasion, osteogenesis and
angiogenesis in several cancers. New vessels forming in
tumours are characterized by high densities of ETA receptors
in smooth muscle, for example in glioblastoma multiforme in
the brain (Harland et al., 1998). Conversely, ETB receptors
may oppose tumour progression by promoting apoptosis and
clearing ET-1 (Bagnato et al., 2011; Rosanò et al., 2013b). The
strategy of stimulating ETB receptors to cause transient
vasodilatation is being developed to increase the penetration
of cytotoxic anti-tumour agents into tumours and to mini-
mize the concentration in healthy tissue.
IRL1620 was originally developed as a tool compound
(Takai et al., 1992). The N-terminus has an N-succinyl modi-
fication, which is likely to reduce metabolism by non-specific
peptidases, but it is not orally active and requires injection.
Despite these unpromising pharmacokinetic features, it is
being used in vivo and has emerged as a possible clinical
candidate in improving the delivery of drugs to tumours.
IRL1620 infused into rats improved the efficacy of doxoru-
bicin and 5-flurouracil by significantly increasing the amount
of drug in tumours in rat models of prostrate and breast
cancer. In addition, radiation-induced reduction in tumour
volume was enhanced, suggesting IRL1620 can significantly
increase the efficacy of radiotherapy in the treatment of solid
tumours. The results suggest that for a given dose of drug, the
efficacy in reducing the tumour could be improved (Gulati
and Rai, 2004; Rajeshkumar et al., 2005a,b; Lenaz et al., 2006;
Rai et al., 2006; Gulati et al., 2012). A phase I trial to deter-
mine the safety, tolerability, pharmacokinetics and pharma-
codynamics of IRL1620 (known as SPI-1620 licensed by
Spectrum Pharmaceuticals, Technology Drive Irvine, CA,
USA) in patients with recurrent progressive carcinoma has
been successfully completed and shown to selectively and
transiently increase tumour blood flow (Gulati et al., 2012;
http://www.cancer.gov/clinicaltrials). A phase II trial was ini-
tiated in 2013 to determine the effectiveness of SPI-1620 in
combination with docetaxel in patients with advanced bili-
ary cancer (http://clinicaltrials.gov/ct2/show/NCT01773785)
and in combination with docetaxel compared with docetaxel
alone for patients with non small-cell lung cancer after failure
of platinum-based chemotherapy (http://clinicaltrials.gov/
show/NCT01741155).
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ETB agonists in neuroprotection
The human brain contains the highest density of ET recep-
tors, with the ETB receptor subtype comprising about 90%, in
areas such as cerebral cortex (Harland et al., 1998). Binding
and functional studies have demonstrated glia mainly express
ETB receptors whereas ETA receptors are localized mainly on
neurones (Morton and Davenport, 1992). Smooth muscle
cells from large arteries and small intracerebral vessels only
express ETA receptors (Adner et al., 1994; Harland et al., 1995;
Pierre and Davenport, 1999) with endothelial cell ETB recep-
tors mediating relaxation (Lucas et al., 1996). The small pial
arteries and arterioles penetrating into the brain play a major
role in the maintenance of cerebral blood flow (auto-
regulation). These vessels are particularly sensitive to ET-1
compared with peripheral vessels and the peptide has been a
long-standing candidate in the genesis or maintenance of
cerebrovascular disorders such as delayed vasospasm associ-
ated with subarachnoid haemorrhage or stroke. ET-1 does not
cross the blood–brain barrier from the plasma, but may do so
when compromised by subarachnoid haemorrhage, stroke or
head injury. Strategies for targeting cerebrovascular disease
have focused previously on the use of ET receptor antago-
nists, firstly to block vascular receptors mediating cerebrova-
sospasm that may be responsible for delayed cerebral
ischaemia seen after aneurysmal subarachnoid haemorrhage
and could contribute to ischaemic core volume in stroke.
Secondly, to block neural receptors that mediate increases in
intracellular free calcium (Morton and Davenport, 1992) and
initiate the pathophysiological processes leading to neuronal
death.
A new emerging strategy is to use ETB receptor agonists
such as IRL1620 to provide vasodilatation and neuroprotec-
tion. The peptide reduced neurological damage following
permanent middle cerebral artery occlusion in rats, a model
of focal ischaemic stroke. Animals received i.v. injections of
IRL1620 after the occlusion, which dramatically reduced
infarct volume (by more than 80% in the acute and 70% in
the chronic study), prevented cerebral oedema, reduced oxi-
dative stress markers and improved all neurological and
motor function for up to 7 days (Leonard et al., 2011; 2012;
Leonard and Gulati, 2013). Rats treated with the amyloid
peptide Aβ1–40 administered into the intracerebral vessels
display increased markers of oxidative stress in the brain.
IRL1620 significantly reduced oxidative stress and impor-
tantly the cognitive impairment (Briyal et al., 2014). As dis-
cussed later, a reduction in ECE activity is associated with
accumulation of amyloid β-peptide and neurotoxicity early
in progression of Alzheimer’s disease (Eckman et al., 2001;
2003; 2006; Pacheco-Quinto and Eckman, 2013). These
results are limited to disease models in a single species, and it
is unclear whether the molecular mechanisms would trans-
late to humans, but taken together, they suggest that an ETB
receptor agonist might offer a new therapeutic strategy in
Alzheimer’s disease and provide neuroprotection following
cerebral ischaemia in conditions such as stroke.
No evidence for further ETB receptor subtypes
Previous studies have suggested that ETB receptors could be
further subdivided into ETB1 present on endothelial cells and
ETB2 on smooth muscle cells. Studies continue to be pub-
lished with this misleading nomenclature, but current evi-
dence only supports the existence of two subtypes, ETA and
ETB, according to NC-IUPHAR nomenclature (Davenport,
2002; Alexander et al., 2013a,b). Firstly, Mizuguchi et al.
(1997) demonstrated unequivocally that in ETB receptor
knockout mice, both the direct constrictor and indirect vaso-
dilator responses to the ETB agonist sarafotoxin S6C were
abolished. Selective deletion of endothelial ETB receptors in
mice (demonstrated by autoradiography to leave unaltered
ETB receptors expressed by other cell types) impaired, as
expected, the clearance of an i.v. bolus of labelled ET-1 com-
pared with controls (Bagnall et al., 2006; Kelland et al., 2010).
Secondly, Flynn et al. (1998) were unable to distinguish phar-
macologically, in extensive competition-binding experi-
ments, between ETB receptors expressed by human isolated
endothelial and smooth muscle cells in culture. In concord-
ance, saturation-binding assays in human tissue always found
ETB radiolabelled ligands bound with a single affinity and Hill
slopes close to unity with no suggestion of further subtypes
(Molenaar et al., 1992; 1993; Nambi et al., 1994) or in
competition-binding versus radiolabelled ET-1 in human
native (Peter and Davenport, 1995; 1996; Russell and
Davenport, 1996) or recombinant ETB receptors (Nambi et al.,
1994; Reynolds et al., 1995). Clozel and Gray (1995) showed
that endothelial and smooth muscle ETB receptors cannot be
distinguished functionally.
Do ETs interact with any other GPCRs?
The virtually complete sequencing of the human genome has
allowed the identification of all of the human gene sequences
that could potentially encode GPCRs that are currently clas-
sified as ‘orphan’ to indicate that their endogenous ligand is
not yet known (Foord et al., 2005; Davenport et al., 2013). In
this catalogue, the most closely related to the ETA and ETB
receptor subtypes are the orphan receptors GPR37 (also know
as ET receptor type B-like or Parkin-associated ET receptor-like
receptor) and its related receptor, GPR37L1. A recent high-
throughput screen tested ∼10 000 biologically active com-
pounds for binding to 82 remaining orphan GPCRs. None of
the ∼20 ET peptides tested at high concentration (including
all three mature isoform and their corresponding big ET pre-
cursors, C-terminal metabolites, BQ123 and the ETB receptor
agonist BQ3020) activated any of the expressed receptors,
including GPR37 or GPR37L, supporting the established
concept of ETs binding to only two receptor subtypes. Two
orphan neuropeptides, prosaptide and prosaposin, have
recently been proposed as cognate ligands for GPR37 and
GPR37L (Meyer et al., 2013).
Clinical application of ET antagonists
Bosentan, ambrisentan and withdrawal
of sitaxentan
PAH is a progressive condition with no cure and has a major
impact on the ability to lead a normal life. It is an orphan
disease (∼100 000 patients in US and Europe). PAH involves
constriction of pulmonary arteries and is characterized by
high BP in the lungs, ultimately leading to right heart failure
and death. A number of pathways have been implicated in
the development of PAH including bone morphogenetic
BJP J J Maguire and A P Davenport
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proteins, prostacyclin and ET-1. Restoring the imbalance
between constriction and vasodilatation of blood vessels is
the basis for current medical therapies, although the cause of
death is right heart failure. Although ETA receptors are signifi-
cantly increased in the right ventricle of patients with PAH
(Kuc et al., 2014) and in the left ventricle of patients with
heart failure (Zolk et al., 1999), surprisingly, ET receptor
antagonists have clinical efficacy in the former, but not the
latter group (Kohan et al., 2012).
Bosentan (Tracleer, Ro47-0203) was the first ET receptor
antagonist to be introduced into the clinic for the treatment
of PAH (Rubin et al., 2002) and, as an orally acting agent, at
the time represented a major advance over existing therapies
such as prostacyclin analogues. Bosentan is classified as a
mixed ETA/ETB receptor antagonist blocking both receptors
(Figures 2 and 3). The second antagonist to enter the clinic in
2007 was ambrisentan (Letairis, Volibris, LU208075, Figures 2
and 3), which was reported to display some ETA receptor
selectivity (Vatter and Seifert, 2006) followed by the most
highly selective ETA receptor antagonist sitaxentan (Thelin,
TBC11251) (Barst et al., 2004). While hepatotoxicity is a
known side effect of ET antagonists, it is usually reversible
and related to dose. Unfortunately, cases of idiosyncratic
hepatitis resulting in acute liver failure leading to death have
been reported with sitaxentan and the compound was with-
drawn in 2010 (Don et al., 2012).
Next generation of ET antagonists:
macitentan
Despite the current use of ET receptor antagonists and drugs
targeting the two other principal pathways- that of NO with
PDE5 inhibitors and that involving prostacyclin (PGI2) –
meta-analysis of PAH trials shows existing therapies only
moderately increased the most widely used objective evalua-
tion of functional exercise capacity (6 min walk distance) by
11%. The prognosis for patients with PAH remains poor with
∼15% mortality within 1 year. There remains an urgent need
for new efficacious treatments that has lead to the develop-
ment of macitentan.
Macitentan (Opsumit, ACT-064992, Figures 2 and 3) rep-
resents the next generation of orally active ET receptor
antagonists and was developed by modifying the structure of
bosentan to improve efficacy and tolerability (Bolli et al.,
2012). Macitentan is described as a dual antagonist that
blocks both ETA and ETB receptors and it inhibited [125I]-ET-1
binding to human recombinant ETA receptors with an IC50 of
0.2nM and to ETB receptors with an IC50 of 391 nM. On the
basis of these results, macitentan displays about 800-fold
Figure 2
Structures of ET receptor antagonists in clinical use bosentan, ambrisentan and macitentan. The structures of the NEP/ECE inhibitor pro-drug
SLV306 and its active metabolite are also shown.
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selectivity. A phase III clinical trial was successfully com-
pleted in 2012 (Pulido et al., 2013), and the compound
gained approval from the US FDA in 2013 for the treatment
of PAH. Macitentan is metabolized by the cytochrome P450
system, predominantly CYP3A4 and to a lesser extent the
CYP2C19 iso-enzyme. Unlike other antagonists currently in
use, one of the metabolites of macitentan, ACT-132577
(Figure 2), is pharmacologically active. Although it has a
lower potency than the parent compound ACT-132577
reaches higher plasma concentrations, with a longer half-life
of about 48 h (Iglarz et al., 2008; Sidharta et al., 2011;
2013a,b). These factors are likely to contribute to improved
activity of macitentan compared with bosentan. While in
vitro studies suggested macitentan was likely to interact with
other drugs (Weiss et al., 2013), other observed pharmacoki-
netic benefits included fewer interactions with other drugs at
clinically used concentrations, no requirement to alter doses
in patients with renal or hepatic impairment, improved
hepatic safety and reduced oedema/fluid retention compared
with bosentan. Key differences were also identified in the
pharmacodynamic parameters. For example, in calcium
release assays macitentan was more potent (KB = 0.1 nM) than
bosentan (KB = 1.1 nM) and had a significantly longer recep-
tor occupancy (17 min compared with 70 s) (Iglarz et al.,
2008; Bruderer et al., 2012a,b; 2013; Gatfield et al., 2012). The
authors suggested that the macitentan binding site differed
slightly from the bosentan binding site and that this differ-
ence in interaction with amino acids in the receptor contrib-
uted to the slow dissociation of macitentan from the receptor,
particularly leading to insurmountable antagonism. A
number of clinical trials are actively recruiting (Patel and
McKeage, 2014) including the use of macitentan for the treat-
ment of digital ulcers in patients with systemic sclerosis,
Eisenmenger’s syndrome and, perhaps the most challenging,
in patients with brain tumours (glioblastoma).
Compounds interacting with ET-1
synthesis and metabolism
Members of the neprilysin (NEP)-like family of zinc metal-
loendopeptidases play key roles in the ET pathway (Turner
and Murphy, 1996; Turner et al., 2001). Neutral endopepti-
dase (NEP) is a membrane-bound thermolysin-like zinc met-
alloendopeptidase, which is particularly abundant in human
kidneys. The enzyme metabolizes a number of peptides
including enkephalins, tachykinins, natriuretic peptides as
well as the ETs (Turner and Tanzawa, 1997). Inactivation of
ET-1 is via a two-stage process, opening of the Ser5–Leu6 bond,
followed by cleavage at the amino side of Ile19 resulting in an
inactive peptide, which is inhibited by phosphoramidon
(Skolovsky et al., 1990). Pharmacological intervention in the
pathway is challenging because NEP-like enzymes also
include the synthetic enzymes ECE-1, ECE-2 and KELL. The
ECEs are also inhibited by phosphoramidon and ECE inhibi-
tors currently in clinical trials have significant NEP inhibitory
activity and it seems counter-intuitive to inhibit the degra-
dative pathway. However, in practice, inactivation of ET-1 is
thought to be mainly via binding and internalization of the
ETB receptor and ET-1 is essentially stable in plasma. Binding
to ETB receptors, particularly in those organs such as the lung
expressing high densities of the subtype, are critical for inac-
tivation of the peptide. After internalization of the ligand–
Figure 3
Selectivity of ET receptor antagonists for ETA versus ETB receptors shown on the vertical axis as reported by the companies that discovered the
compounds. Selectivity was mainly determined by measuring affinity constants in separate competition assays against [125I]-ET-1 using human
recombinant ETA versus ETB receptors and may not reflect selectivity measured in clinically relevant native tissues. Bosentan, ambrisentan and
macitentan are currently approved for clinical use and are highlighted.
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receptor complex to the lysosome, ET-1 is thought to be
degraded, like other peptides, by cathepsin A. In support,
cathepsin A knockout mice showed reduced ET-1 degradation
and significantly increased arterial BP. In humans, genetic
defects of cathepsin A include hypertension and cardiomyo-
pathies (Seyrantepe et al., 2008).
ECE-1
It is now well established that ET is synthesized in a three-step
process, with pre-pro-ET-1 initially cleaved by a signal pepti-
dase to proET-1, which is in turn cleaved by a furin enzyme to
an inactive precursor big ET-1 (Figure 1). Although low MW
inhibitors of furins have been reported, furins cleave a
number of other proteins to mature or active forms and
therefore are not an easy tractable drug target for selectively
reducing ET-1, without altering other pathways. Targeting the
ECE enzymes responsible for transformation of big ET-1 to
the mature, biologically active ET-1 has been more promising
(Xu et al., 1994; Turner and Murphy, 1996). In humans there
are four isoforms, ECE-1a–d, derived from a single gene by the
action of different promoters. Structurally, they differ only in
the amino acid sequence of the extreme N-terminus. ECE-1
localizes to the small secretory vesicles of the constitutive
pathway from where ET-1 is continuously released to main-
tain normal vascular tone. Unusually for vasoactive peptides,
ET-1 is also synthesized by ECE-1 and stored in specialized
Weibel–Palade bodies within endothelial cells until its release
following an external physiological or pathophysiological
stimulus (the regulated pathway) to produce further vasocon-
striction (Russell et al., 1998a,b; Russell and Davenport,
1999b).
In addition to intracellular endothelial cell ECE, the
enzyme is also present on vascular smooth muscle, efficiently
converts big ET-1 in human vessels in vitro and is up-regulated
in atherosclerosis (Maguire et al., 1997; Maguire and
Davenport, 1998). Given the larger volume of the smooth
muscle compared with the single layer of endothelium,
smooth muscle ECE may be a more important source of ET-1
in pathophysiological conditions.
ECE-2
ET-1 is also synthesized by a second membrane-bound met-
alloprotease, ECE-2 (Emoto and Yanagisawa, 1995;
Yanagisawa et al., 2000; Lorenzo et al., 2001) with ∼60%
sequence similarity to ECE-1. It is distinguishable from ECE-1
by having an optimum pH of 5.5 for activity. In human
endothelial cells, ECE-2 was localized to the acidified envi-
ronment of vesicles of the secretory pathway, but unlike
ECE-1 it is not found in storage granules (Russell and
Davenport, 1999b). Four isoforms exist, differing in their
N-terminus: ECE-2a-1 and ECE-2a-2 are expressed predomi-
nantly in peripheral tissues and ECE-2b-1 and ECE-2b-2 in
the brain, possibly representing the neuronal isoforms (Ikeda
et al., 2002). The physiological importance of this pathway
for ET-1 synthesis remains to be determined, as ECE-2 also
metabolizes other peptides such as bradykinin. However, the
requirement for an acidic pH suggests a role in pathophysi-
ological conditions associated with low pH such as ischaemia.
ECE-1/ECE-2 knockout mice display increased developmental
defects compared with deletion of ECE-1 or ECE-2.
Alternative, non-ECE synthetic
pathway: chymase
ET-1 can also be synthesized indirectly by chymase, a serine
protease present in mast cells. Big ET-1 is converted to ET-11–31
by cleaving the Tyr31–Gly32 bond (Figure 1), which in turn is
converted to the mature peptide via Trp21–Val22 bond (Fecteau
et al., 2005; D’Orleans-Juste et al., 2008). The existence of an
alternative pathway was originally predicted when ET-1 and
ET-2 were detected in embryos of the ECE-1/ECE-2 double-
knockout mouse (Yanagisawa et al., 2000).
The importance of this alternative pathway remains
unclear, but importantly ET-11–31 was equipotent with big
ET-1 in causing vasoconstriction in human isolated vessels,
including coronary arteries, and this was associated with the
appearance of measurable levels of ET-1 in the bathing
medium. ET-11–31 displayed no selectivity between ETA and
ETB receptors in human heart and vasoconstriction was fully
blocked by ETA receptor selective antagonists, reflecting the
predominance of the ETA receptor on vascular smooth muscle
(Maguire et al., 2001; Maguire and Davenport, 2004). The
precise physiological role of mast cells within human blood
vessels is unclear, but following degranulation, which may
occur under pathophysiological conditions, the mast cell
chymase is associated with interstitial spaces with the poten-
tial to convert circulating big ET-1 and provide a further
source of ET-1. Mast cell expression is increased in cardiovas-
cular disease, for example in atherosclerotic lesions. It is
therefore possible that the contribution of this pathway
within the vasculature, leading to over-expression of ET-1,
may be underestimated particularly in conditions of endothe-
lial malfunction where opposing levels of endogenous vaso-
dilators may be reduced. It is unclear whether under
conditions of NEP/ECE inhibition the rising levels of big ET-1
would favour increased conversion by the serine protease
pathway, thus increasing the pressor effect via ETA receptors
or whether excretion of unmetabolized big ET-1 by the
kidney would be sufficient to remove the elevated levels of
precursors (Johnström et al., 2010).
KELL and ET-3 synthesis
Although big ET-3 is converted by ECE-1 to ET-3, owing to
difference in the C-terminus the efficiency is much less than
for ET-1. In contrast, big ET-3 is reported to be efficiently
converted by KELL (Lee et al., 1999). KELL is a membrane-
bound glycoprotein expressed in human erythrocytes and
one of the major antigens; it is also related to mammalian
NEP-like enzymes including ECE-1 and ECE-2 (Turner and
Tanzawa, 1997). If KELL is the main synthetic pathway for
ET-3, a possible benefit of inhibiting ECE would be to increase
the ratio of ET-3 to ET-1, which could then differentially
produce beneficial vasodilatation via the ETB receptor, but
this speculative hypothesis has not been tested.
Pharmacological inhibition of ECE by
research compounds
A combination of phosphoramidon and thiorphan has been
widely used to identify ECE activity. This is based on the
finding that the conversion of big ET-1 to ET-1 is inhibited by
phosphoramidon, but not by thiorphan, and has been shown
both in vitro and in vivo. Importantly for evaluating the sig-
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nificance of animal models, both compounds have also been
used in clinical studies to characterize big ET-1 conversion
(see Webb, 1995; Plumpton et al., 1996a; Hand et al., 1999).
Low MW, non-peptide ECE inhibitors have been developed
and one that has been widely used in vitro and in vivo animal
models and is commercially available is CGS26303 (De
Lombaert et al., 1994). CGS26303 inhibited conversion of all
three big ETs in human isolated blood vessels but, impor-
tantly, did not interfere with the interaction of mature pep-
tides with ET receptors (Yap et al., 2000). Although primarily
an NEP inhibitor, SOL1, a more recent combined NEP/ECE
non-peptide inhibitor with modest inhibition of ECE-1 in
vitro, was remarkably potent in vivo, fully blocking the big
ET–1-induced rise in BP at a dose of 10 μmol·kg−1 (Nelissen
et al., 2012).
A disadvantage of using phosphoramidon is that it is not
selective for ECE. An alternative tool compound is PD159790,
which inhibits ECE-1 with an IC50 value of 3 μM; at this
concentration the compound is selective for ECE-1 over NEP
(Ahn et al., 1998). PD159790 has been shown experimentally
in HUVECs to inhibit conversion of big ET-1 at pH 6.9,
optimum for ECE-1, but did not affect big ET-1 conversion to
the mature peptide at pH 5.4, optimum for ECE-2 (Russell
and Davenport, 1999a). The compound did not inhibit the
further metabolism of ET-11–31, the chymase product of big
ET-1 (Maguire et al., 2001) and can be used to distinguish
between the three different pathways for ET synthesis. While
the mature peptide is located in intracellular Weibel–Palade
bodies or secretory vesicles within endothelial cells and a
proportion of big ET-1 is converted to ET-1 intracellularly, it is
not reported whether ECE inhibitors can cross the plasma
membrane to access these intracellular sites. The main effects
of these inhibitors may be on external ECE. In agreement
with this proposal, the SLV306 metabolite KC-12615 (see
later) effectively prevented conversion of exogenous big ET-1
in human vasculature (Seed et al., 2012).
Emerging NEP/ECE inhibitors
Selective inhibitors of ECE have not progressed into clinical
applications. SLV306 (daglutril, Figure 2) is an orally active,
mixed enzyme inhibitor of both ECE and NEP. It is a pro-drug
being converted in vivo to the active metabolite, KC-12615.
This latter molecule has a pharmacological profile similar to
phosphoramidon, inhibiting NEP in the nanomolar range,
but with more modest inhibition in the micromolar range for
ECE (Meil et al., 1998; Jeng et al., 2002). The therapeutic basis
is that while inhibition of NEP alone increased plasma con-
centrations of atrial natriuretic factor (ANP) to cause vasodila-
tation, NEP inhibitors are ineffective as anti-hypertensives,
probably because NEP also degrades vasoconstrictor peptides
including ET. A combined ECE/NEP inhibitor would be pre-
dicted to reduce the systemic conversion of big ET-1 to the
mature peptide and increase dilator peptides such as ANP.
SLV306 is well tolerated with few or none of the side effects
such as increases in liver function, oedema, observed with ET
receptor antagonists (Dickstein et al., 2004; Parvanova et al.,
2013). A potential disadvantage is big ET-1 might still be
converted to ET-1 by an alternative pathway such as chymase.
However, in animal models with normal renal function, this
did not occur and big ET-1 labelled with the positron emitter
18F was rapidly accumulated unchanged in the kidney follow-
ing inhibition of NEP/ECE, with no evidence of conversion
by another pathway (Johnström et al., 2010).
The effect of a combined NEP/ECE inhibitor has been
tested in volunteers in a randomized, double-blind trial. Fol-
lowing oral administration of three increasing doses of
SLV306 (to reach an average target concentration of 75, 300,
1200 ng·mL−1 of the active metabolite KC-12615), big ET-1
was infused into 13 male volunteers at a rate of 8 and
12 pmol·kg−1·min−1 (20 min each). At the two highest concen-
trations tested, SLV306 dose-dependently attenuated the rise
in BP after big ET-1 infusion. There was a significant increase
in circulating big ET-1 levels compared with placebo, indicat-
ing that SLV306 was inhibiting an increasing proportion of
endogenous ECE activity. Importantly, plasma ANP concen-
trations also significantly increased, consistent with systemic
NEP inhibition (Seed et al., 2012).
SLV306 in animal models and patients with
type 2 diabetes and nephropathy
Diabetes causes activation of the renal ET system, which leads
to progressive renal damage by cell proliferation and intersti-
tial inflammation. Inhibitors of the renin–angiotensin system
are widely used in treatment for hypertensive patients with
type 2 diabetes, but are less effective in the advanced stages of
diabetic renal disease. Studies in an animal model suggested
that SLV306 had a similar efficacy to the angiotensin convert-
ing enzyme (ACE) inhibitor captopril in reducing proteinuria
and preventing nephrosclerosis (Thone-Reinke et al., 2004).
In this study, rats were treated with streptozotocin for twenty
weeks and the effects of SLV306 (30 mg·kg−1 per day) com-
pared with those of captopril (10 mg·kg−1 per day). SLV306
significantly decreased renal interstitial matrix content as
well as protein and albumin excretion in diabetic rats, inde-
pendent of BP and was as effective as captopril. These results
suggested SLV306 treatment on top of blocking the renin–
angiotensin system might have an additional benefit in
reducing BP and improving renal function.
Parvanova et al. (2013) tested the efficacy of SLV306 in 45
patients with type 2 diabetes mellitus who had albuminuria
and were already receiving the angiotensin receptor antago-
nist losartan, together with up to two additional anti-
hypertensive drugs, in a randomized, crossover, double-blind,
placebo-controlled trial. Although 8 weeks of treatment with
SLV306 together with losartan did not significantly alter
urinary albumin excretion or renal haemodynamic measures,
the authors showed for the first time that the combination
decreased ambulatory BP (particularly for systolic hyperten-
sion) in this patient group that are often resistant to treat-
ment. There was a small, but significant increase in plasma
big ET-1, consistent with ECE inhibition, but surprisingly not
in pro-ANP. Increases in the natriuretic peptides was meas-
ured in healthy volunteers by Seed et al. (2012). Interestingly,
the effect of SLV306 in this study on BP was higher at night
(10 versus 12 mmHg). This is of potential importance as
increased hypertension at night is a strong cardiovascular risk
factor in this patient population. The molecular mechanism
is not yet known, as plasma levels of big ET-1 were not
reported separately for daytime versus night. The study was
comparatively short and did not reveal significant changes in
albumin excretion as predicted from animal studies. Long-
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term trials are required to determine whether the observed
lowering of BP by SLV306 will translate into longer-term renal
and cardio-protection.
SLV306 and congestive heart failure
The effect of three single oral doses of SLV306 was tested in
patients with congestive heart failure who underwent right-
sided heart catheterization in a randomized, double-blind,
placebo-controlled design (Dickstein et al., 2004). Pulmonary
pressures and right atrial pressure decreased significantly in
all SLV306 dose groups with the maximum decrease occur-
ring at 6–8 h. Despite plasma levels of the drug increasing
with dose, there was no clear dose–response relationship,
which may have been the result of the comparatively small
numbers (18–20) in the study.
Insight in NEP/ECE inhibition from
animal models
The efficacy of inhibiting NEP/ECE in animal models associ-
ated with increases in the ET signalling pathway has provided
clues to future clinical applications. The development of
nephropathy in diabetes is associated with a poor outcome,
eventually leading to end-stage renal disease. In patients with
diabetes, urinary excretion of protein and albumin rises and
is associated with increased risk of cardiovascular disease. In
diabetic rats, SLV306 decreased renal matrix protein content,
protein and albumin excretion. The magnitude of these
effects was comparable to those of ACE inhibition and inde-
pendent of BP (Thone-Reinke et al., 2004). Currently, there
are few drugs for the treatment of chronic renal failure.
SLV338, a NEP/ECE inhibitor, abolished renal tissue damage
(interstitial fibrosis, glomerulosclerosis, renal arterial remod-
elling) in rat models of both acute kidney failure as well
as chronic renal failure. The compound preserved kidney
function and reduced mortality (Sharkovska et al., 2011). In
spontaneously hypertensive stroke-prone rats, SLV338 signifi-
cantly improved survival in comparison with the vehicle-
treated group in a BP-independent manner and could offer a
new therapeutic approach for primary stroke prevention and
improvement of mortality (Wengenmayer et al., 2011).
SLV338 was also tested for cardiac protection in rat model of
experimental renovascular hypertension (two-kidney, one-
clip). SLV338 prevented cardiac remodelling to the same
extent as losartan, but in a BP-independent manner. This
effect was at least partly mediated via suppression of cardiac
TGF-β1 expression (Kalk et al., 2011).
ET has been proposed to be a mediator in toxic liver
injury. However, while SLV338 largely prevented the activa-
tion of the ET system it did not prevent D-galactosamine-
induced acute liver injury in rats. The authors speculated that
SLV388 should be tested in a less severe model of liver injury,
as very severe intoxication might not be relevantly amenable
to pharmacological interventions (Hocher et al., 2011).
ECE-1 and amyloid deposition
The strategy in the cardiovascular and renal systems has been
to inhibit ECE-1 activity. However, evidence is emerging that
ECE-1 may function in the brain as a novel enzyme degrading
amyloid β-peptides at several sites. Deposition of amyloid in
the brain in Alzheimer’s disease is determined not only by its
production, but also by its catabolism. ECE-1 inhibition pro-
duces, in addition to extracellular accumulation, accumula-
tion of intracellular amyloid β-peptides within endosomal/
lysosomal and autophagic vesicles and an intracellular pool,
is partly regulated by ECE activity at the sites of production.
Reduction in ECE activity leads to accumulation of amyloid
β-peptide, which is associated with neurotoxicity early in
progression of Alzheimer’s disease (Eckman et al., 2001; 2003;
2006; Pacheco-Quinto and Eckman, 2013). The clearance of
Aβ1–40 in mice was almost completely inhibited by phospho-
ramidon as well as insulin indicating that human Aβ1–40 was
degraded, at least in part, by a phosphoramidon-sensitive
pathway, implicating both ECE and NEP (Ito et al., 2013).
To date, these investigations have comprised in vitro or in
vivo rodent studies It is not yet clear whether enhancing ECE-1
activity is a potential drug target in Alzheimer’s disease rather
than inhibiting ECE-1, as in the periphery. ECE-like immu-
noreactivity has been localized to afferent and efferent fibres
of neurones and neuronal cell bodies of mixed morphology
in human brain (Giaid et al., 1991). Drugs increasing ECE
activity such as enzyme enhancers or recombinant ECE
would have to cross the blood–brain barrier, and it is not clear
what effect this would have on ET signalling in the periphery.
What are the new ET drug targets in
the future?
Epigentics
Epigenetics can be defined as heritable changes in phenotype
through mechanisms other than changes in DNA sequence.
Epigenetic changes will therefore be preserved when cells
divide and affect normal development and disease progres-
sion. Processes mediating epigenetic regulation include DNA
methylation and histone modification, which involves post-
translational covalent modification of histone proteins by a
range of writers, erasers and readers. This in turn modulates
the ability of associated DNA to be transcribed. The histone
code is read by specific families of proteins such as the
bromodomains. These are of pharmacological significance
because of the recent discovery of low MW inhibitors, which
selectively modulate gene expression (Prinjha et al., 2012).
Epigenetic regulation is of particular importance in the ET
pathway with transcription being the primary level of ET-1
regulation of the gene EDN1 by histone modifications and
DNA methylation (Welch et al., 2013). Silencing of the
EDNRB gene by DNA methylation during development of
tumours results in the down-regulation of the receptor. As a
result, promotion of apoptosis via the ETB receptor is reduced
or lost, suggesting the ETB receptor could be a target for
epigenetic drugs or ETB agonists where ET may be the cause of
some tumour types, including melanomas and oligodendro-
gliomas (Bagnato et al., 2011). Intriguingly, epigenetic inacti-
vation of ET-2 and ET-3 mRNA and protein was found in rat
and human colon tumours and cancer cell lines, as a result of
hypermethylation of EDN2 and EDN3 genes. Restoring
expression of ET-2 and ET-3 in human cells significantly
attenuated the migration and invasion of human colon
cancer cells (Wang et al., 2013). As ET-3 displays high affinity
for the ETB receptor, forced expression of ET-3 might
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antagonize the actions of ET-1 mediated through ETA recep-
tors. Such a mechanism would be consistent with proposed
beneficial effects of the ETB receptor agonist, IRL-1620, in
cancer.
Life before birth – is ET a critical pathway?
Maternal malnutrition and uteroplacental vascular insuffi-
ciency causes foetal growth restriction or intrauterine growth
retardation. Low birthweight is linked to the later develop-
ment of cardiovascular disease and hypertension. Maternal
treatment with dexamethasone increased ET-1 constrictor
responses and ETA receptor expression in placental arteries
from the foetus (Docherty et al., 2001; Kutzler et al., 2003).
Maternal nutrient restriction increased the histone acetyla-
tion and hypoxia inducible factor-1α (HIF-1α) binding levels
in the ET-1 gene promoter of pulmonary vein endothelial
cells (PVECs) in intrauterine growth restriction (IUGR)
newborn rats, and continued up to 6 weeks after birth. These
epigenetic changes could result in an IUGR rat being highly
sensitive to hypoxia later in life, causing more significant
PAH or pulmonary vascular remodelling. Recently, Xu et al.
(2013) have shown that restricting the diets of pregnant rats
so that they were undernourished increased the histone
acetylation and HIF-1α binding levels in the proximal pro-
moter region of ET-1, up-regulating the expression of ET-1,
and this continued for 6 weeks after birth of the offspring.
The authors speculate that that this intrauterine growth retar-
dation could cause varying degrees of PAH later in life.
Generally, increased levels of histone acetylation are
associated with increased transcriptional activity, whereas
decreased levels of acetylation are correlated with suppressed
gene expression. These data show that the open chromatin
domains marked by histone H3 and H3K9/18 acetylation at
the proximal promoter of ET-1 in IUGR rats are essential for
transcription. Up-regulated ET-1 protein expression in PVEC
from IUGR hypoxia rats is closely associated with the pres-
ence of increased acetylated H3 histones.
Biased signalling in the ET pathway
Pharmacology is undergoing a revolution in understanding
the mechanism of ‘biased signalling’ via GPCRs. It was origi-
nally thought that ligands binding to a receptor would
equally activate the G-protein pathway to produce a physi-
ological response such as vasoconstriction (such as ET-1
acting on an ETA receptor) as well as activating the β-arrestin
pathway, which eventually leads to desensitization, receptor
internalization and ‘silencing’ of the pathway. It is now
clear that some ligands are biased to one pathway over the
other and secondly, rather than silencing, β-arrestin can
activate alternative signalling pathways, some of which may
be pathophysiological leading to longer-term signalling
responses such as migration and proliferation.
Both ET receptor subtypes follow an β-arrestin and
dynamin/clathrin-dependent mechanism of internalization,
but it has been established that ETA receptors are recycled to
the plasma membrane for further signalling while ETB recep-
tors are targeted to lysosomes and degraded (Bremnes et al.,
2000). In epithelial ovarian cancer, activation of ET-1/ETA
receptor signalling is linked to many tumour-promoting pro-
cesses including proliferation, angiogenesis, invasion and
metastasis. NF-κB is an important signalling molecule in
immunity, inflammation and cancer and β-arrestin is
required for ET–1-induced NF-κB activation (Cianfrocca et al.,
2014). ET-1 promoted podocyte migration via ETA receptors
and increased β-arrestin-1, sustaining renal injury, a pathoge-
netic pathway that can affect podocyte phenotype in prolif-
erative glomerular disorders (Buelli et al., 2014). β-Arrestin-1
has also been found to be a nuclear transcriptional regulator
of ET–1-induced β-catenin signalling, an important mecha-
nism for controlling cell division and progression of epithe-
lial ovarian cancer and necessary for epigenetic modification,
such as histone acetylation, and gene expression (Rosanò
et al., 2009; 2013a). In addition, these effects are blocked by
ET receptor antagonists and support a role for ETA-mediated/
β-arrestin-1 facilitating inter-protein interaction in invasive
and metastatic behaviour of ovarian cancer.
Biased ET ligands?
Agonists that are biased towards β-arrestin signalling for para-
thyroid hormone and angiotensin AT1 receptors have been
identified. G-protein pathway-selective agonists have been
identified for nicotinic acid (nomenclature revised by
NC-IUPHAR to hydroxycarboxylic acid) and μ-opioid recep-
tors (Luttrell, 2014). The race is now to determine whether
such strategies can be exploited therapeutically.
Do biased ligands (ligands that binding to the same recep-
tor but activate different signalling pathways) exist for ET
receptors? The study by Compeer et al. (2013) already men-
tioned suggested ET-1 and ET-2 initiate and maintain vaso-
constriction by different downstream mechanisms. Biased
signalling can be identified by comparing the affinities of
ligands in β-arrestin recruitment assays with a G–protein-
mediated response such as vasoconstriction (Maguire et al.,
2012). In this study the rank order of potency for β-arrestin
recruitment at the ETA (ET-1 ≥ ET-2 > > ET-3) and ETB (ET-1 =
ET-2 = ET-3) receptors was as expected and there was no
obvious major differences in potency of ETs when comparing
with G–protein-mediated constrictor assays in human
vessels. However, at the ETA receptor sarafotoxin S6b was a
partial agonist in β-arrestin recruitment, but a full agonist in
causing constriction, suggesting the possibility of biased
ligands. Such a bias could have been selected for during
evolution by prolonging the effects of envenomation of the
mammalian prey. While bosentan displays no selectivity for
ETA over ETB receptors in radioligand binding and G-protein
functional assays, unexpectedly, it was significantly more
effective an inhibitor of β-arrestin recruitment mediated by
ETA, compared with the ETB receptors (Maguire et al., 2012).
The result for bosentan is intriguing as many of the detrimen-
tal actions of ET-1, particularly in cancer, may use the
β-arrestin pathway, and this suggests the potential to block a
deleterious pathway while preserving activation of a benefi-
cial pathway.
The next 25 years – quo vadis?
Since the discovery of ET, intense medicinal chemistry pro-
grammes have identified receptor antagonists, ETB receptor
agonists and inhibitors of the key synthetic enzyme, ECE-1.
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Both mixed ETA/ETB and ETA selective receptor antagonists
have become established in the treatment of PAH, while
NEP/ECE inhibitors such as SLV306 have promise as an alter-
native to receptor blockade and IRL1620 and other ETB recep-
tor ligands have potential in improving cancer therapy.
All of these are approaches that have exploited low MW
compounds. Over 50 therapeutic monoclonal antibodies
have been approved for clinical use, but none yet against a
GPCR target, emphasizing the technical challenge. Endomab-
B1, a monoclonal antibody has recently been reported to
bind with subnanomolar affinity for the ETB receptor,
competed with ET-1 binding with greater efficacy than
BQ788, and functions as an antagonist to block the ET–1-
induced IP3-calcium signalling pathway (Allard et al., 2013).
Whether this antibody has clinical applications remains to be
discovered.
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